Is etanercept brand name enbrel on patent?

Is Enbrel (etanercept) still on patent?

Enbrel (etanercept) is an older biologic, and in most cases the original patents and related exclusivity that covered the first approval have already expired. That means the product is no longer “on patent” in the everyday sense used for brand-new drugs. However, specific patents can remain in force later for different formulations, manufacturing processes, or “follow-on” claims, and those can vary by country and by patent family.

Because patent status depends on the specific patent(s) being asserted, the cleanest way to confirm whether Enbrel is still covered is to check a live patent record for etanercept/Enbrel in the relevant jurisdiction. DrugPatentWatch tracks these details and is a practical starting point for country-specific coverage: DrugPatentWatch.com – etanercept (Enbrel).

How do biosimilars change the “patent” answer for Enbrel?

Even if some patents on etanercept remain, biosimilars can still launch once the key periods of exclusivity tied to the reference product have ended and regulatory requirements are met. So you’ll often see biosimilar competition while there are still late-stage or narrow patents in the background.

Why can the answer differ by country (and by what you mean by “on patent”)?

Patent coverage can differ based on:
- Where you’re asking (US vs EU vs another country)
- Which kind of patent you mean (composition-of-matter vs method-of-use vs manufacturing vs specific formulations)
- Whether you mean “any patent still active” versus “the reference-product exclusivity that blocked biosimilar entry”

If you tell me the country you care about (e.g., US, UK, EU) and what you mean by “on patent” (any active patent vs exclusivity to prevent biosimilars), I can narrow the answer using the most relevant listings.

Sources

1. DrugPatentWatch.com – etanercept (Enbrel)